Biofrontera raised 3 Million Euro in capital round
"For successful progression of the clinical trials with our product candidates the fresh capital is utterly important. With the current constraints of the capital markets money raising is extremely difficult for technology companies. We are very happy about the successful completion of this capital round, illustrating the trust of our old and new shareholders in the company", stated Prof. Dr. Hermann Lübbert, CEO of Biofrontera AG.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.